Literature DB >> 6852449

Prevalence of delta-antibody among chronic hepatitis B virus infected patients in the Los Angeles area: its correlation with liver biopsy diagnosis.

S Govindarajan, G C Kanel, R L Peters.   

Abstract

The overall prevalence of delta-antibody among 80 patients with chronic infection of hepatitis B virus in the Los Angeles area was found to be 24%. Twenty-three patients had a histologic diagnosis of persistent hepatitis and 57 had chronic active hepatitis with or without cirrhosis. Only 1 patient among those with persistent viral hepatitis had delta-antibody, whereas 18 with chronic active hepatitis had delta-antibody in their sera (p less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6852449

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  18 in total

1.  Prevalence of hepatitis delta (delta) virus infection. A seroepidemiologic study.

Authors:  K M DeCock; B Jones; S Govindarajan; A G Redeker
Journal:  West J Med       Date:  1988-03

2.  Pathology-Important Advances in Clinical Medicine: LD(6)-A Biochemical Sign of Impending Death.

Authors:  P Wolf
Journal:  West J Med       Date:  1984-07

3.  Pathology-Important Advances in Clinical Medicine: Hepatitis-delta-Agent.

Authors:  S Govindarajan
Journal:  West J Med       Date:  1984-07

4.  Pathology-important advances in clinical medicine: heparin-induced thrombocytopenia and thrombosis.

Authors:  J D Cao
Journal:  West J Med       Date:  1984-07

5.  Epidemiology of hepatitis delta virus (HDV) infection.

Authors:  A Ponzetto; B Forzani; P P Parravicini; C Hele; A Zanetti; M Rizzetto
Journal:  Eur J Epidemiol       Date:  1985-12       Impact factor: 8.082

Review 6.  Natural history of the HBsAg carrier.

Authors:  M G Anderson; I M Murray-Lyon
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

7.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Authors:  Christopher Koh; Laetitia Canini; Harel Dahari; Xiongce Zhao; Susan L Uprichard; Vanessa Haynes-Williams; Mark A Winters; Gitanjali Subramanya; Stewart L Cooper; Peter Pinto; Erin F Wolff; Rachel Bishop; Ma Ai Thanda Han; Scott J Cotler; David E Kleiner; Onur Keskin; Ramazan Idilman; Cihan Yurdaydin; Jeffrey S Glenn; Theo Heller
Journal:  Lancet Infect Dis       Date:  2015-07-16       Impact factor: 25.071

8.  Long-term therapy of chronic delta hepatitis with peginterferon alfa.

Authors:  T Heller; Y Rotman; C Koh; S Clark; V Haynes-Williams; R Chang; R McBurney; P Schmid; J Albrecht; D E Kleiner; M G Ghany; T J Liang; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2014-05-11       Impact factor: 8.171

9.  Permanent HBsAg clearance in chronic hepatitis B viral infection following acute delta superinfection.

Authors:  K P Chin; S Govindarajan; A G Redeker
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

Review 10.  Delta hepatitis: molecular biology and clinical and epidemiological features.

Authors:  L B Polish; M Gallagher; H A Fields; S C Hadler
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.